- Home
- TRMD vs NAMS Comparison
TRMD vs NAMS Comparison
Compare TRMD & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TRMD | NAMS |
|---|---|---|
| Founded | 1889 | 2019 |
| Country | United Kingdom | Netherlands |
| Employees | N/A | 100 |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.3B |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | TRMD | NAMS |
|---|---|---|
| Price | $32.40 | $28.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $35.00 | ★ $46.75 |
| AVG Volume (30 Days) | 644.2K | ★ 838.8K |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | ★ 6.61% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $17.96 |
| Revenue Next Year | N/A | $540.65 |
| P/E Ratio | $9.61 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.79 | $16.79 |
| 52 Week High | $32.57 | $42.00 |
Technical Indicators
Market Signals| Indicator | TRMD | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 69.41 | 36.61 |
| Support Level | $29.15 | $23.48 |
| Resistance Level | N/A | $37.25 |
| Average True Range (ATR) | 0.89 | 1.69 |
| MACD | 0.15 | -0.61 |
| Stochastic Oscillator | 95.65 | 7.88 |
Price Performance
Historical ComparisonAbout TRMD TORM plc
TORM plc operates as a shipping company mainly owning and operating a fleet of product tankers. It is engaged in the transportation of refined oil products and clean petroleum products, including gasoline, jet fuel, naphtha and diesel oil. The Company operates through two segments: the Tanker segment and the Marine Engineering segment, deriving the majority of its revenue from the Tanker segment.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.